Top 25 orphan drugs, by 2015 global sales
Roche’s Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.
Roche’s Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.
Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.
CDC report finds prescription painkiller abuse contributed to an increase in heroin use; Novartis heart-failure drug gets FDA approval; Isis Pharmaceuticals obtains orphan-drug designation for volanesorsen
Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
The digital health firm is expanding services to pharma customers, offering to help drugmakers maximize spending on TV and video.
Pfizer exec said biosimilar interchangeability definition not happening anytime soon; AARP launches digital health tech studies with Pfizer and UnitedHealthcare; BMS inks gene therapy collaboration deal
Horizon Pharma’s purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.
The duo hope to begin testing a new treatment within three years.
The $38-million deal expands the reach of rare-disease campaigns.
Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases